Barclays Maintains an 'Overweight' on HCA Holdings (HCA); Thoughts on Accounting Change for HITECH Revenue

November 9, 2011 2:08 PM EST
Get Alerts HCA Hot Sheet
Price: $404.68 -1.71%

Rating Summary:
    23 Buy, 11 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on HCA Holdings (NYSE: HCA) price target of $30.00.

Barclays analyst, Adam Feinstein, said, "HCA filed an 8-K to announce that it revised its accounting for HITECH incentive payments based on SEC guidance, leading to a delay in revenue recognition of these payments. In a nutshell, HCA will recognize less revenue than expected in Q4'11, but still anticipates receiving these payments in 2012. The net result is a $0.28 reduction in Q4'11 EPS and a $210 million impact to revenue and EBITDA, but, HCA confirmed that there will be no impact on cashflow from operations. We suggest that this is a timing issue rather than a reduction in the "earnings power" of HCA over the next year. Finally, HITECH has been a source of confusion for the group following the recent Q3 earnings season, so we expect a continued level of focus on better understanding this issue. With this announcement we are reducing our 2011 EPS estimate to $2.64 (down from $2.92)."

For an analyst ratings summary and ratings history on HCA Holdings click here. For more ratings news on HCA Holdings click here.

Shares of HCA Holdings closed at $25.21 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Barclays, Earnings